Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Pending | |||
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
| Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Leqembi | lecanemab | Alzheimer’s disease | Pending | |||
| Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending | |||
| TBC | momelotinib | Myelofibrosis | Pending | |||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : May 9, 2024